The present invention is directed to substituted pyrrolidine derivatives. Specifically, the present invention provides a compound according to formula III: ## STR1 ## wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein) and salts thereof. The compounds of the present invention are inhibitors of the ATF4 pathway, diseases associated with cancer, precancerous syndrome and activated unfolded protein response pathways such as Alzheimer's disease, spinal cord injury, traumatic brain Injury, ischemic stroke, stroke, diabetes, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease and related prion diseases, progressive supranuclear paralysis, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fiber , Chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, eye disease, arrhythmia In the treatment of organs, in organ transplants and in the transport of organs for transplantation. Thus, the present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention. The present invention is further directed to methods of inhibiting the ATF4 pathway and treating disorders associated therewith with a compound of the invention or a pharmaceutical composition comprising a compound of the invention.本発明は、置換ピロリジン誘導体を対象とする。具体的には、本発明は、式ＩＩＩに従う化合物：【化１】（式中、Ａ、Ｂ、Ｌ１、Ｌ２、Ｌ３、Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、Ｒ６、Ｒ９、Ｒ１０、Ｒ３０、Ｙ１、Ｙ２、ｚ２、ｚ４、ｚ５、およびｚ６は本明細書に定義される通りである）およびその塩を対象とする。本発明の化合物は、ＡＴＦ４経路の阻害剤であり、癌、前癌症候群および活性化された小胞体ストレス応答(unfolded protein response)経路に関連する疾患、例えば、アルツハイマー病、脊髄損傷、外傷性脳損傷、虚血性脳卒中、脳卒中、糖尿病、パーキンソン病、ハンチントン病、クロイツフェルト・ヤコブ病および関連プリオン病、進行性核上麻痺、筋萎縮性側索硬化症、心筋梗塞、心血管疾患、炎症、線維症、肝臓の慢性および急性疾患、肺の慢性および急性疾患、腎臓の慢性および急性疾患、慢性外傷性脳症（ＣＴＥ）、神経変性、認知症、認知障害、アテローム性動脈硬化症、眼疾患、不整脈の処置において、臓器移植において、および移植用臓器
